What is Surfix?
Surfix is dedicated to advancing global health by providing accurate, accessible, and affordable diagnostic solutions for disease detection and management, particularly in underserved Point-of-Care (POC) testing segments. The company has developed a photonic diagnostics platform that offers exceptional sensitivity and accuracy, surpassing traditional laboratory standards. Surfix co-develops POC tests with partners, utilizing innovative technologies to enhance healthcare standards and make advanced diagnostics available globally. Their platform has versatile applications, including drug development and disease monitoring, aiming to transform the healthcare landscape.
How much funding has Surfix raised?
Surfix has raised a total of $9.1M across 1 funding round:
Other Financing Round
$9.1M
Other Financing Round (2022): $9.1M with participation from LioniX International and Qurin Diagnostics
Key Investors in Surfix
LioniX International
LioniX International is a global provider of customized microsystems, specializing in photonic integrated circuits and MEMS, catering to various applications including life sciences.
Qurin Diagnostics
Qurin Diagnostics is a pioneering diagnostic biotech company focused on enhancing early cancer detection through innovative, non-invasive technologies and biomarker extraction methods.
What's next for Surfix?
With its recent major strategic investment, Surfix is poised for significant scaling and further development of its photonic diagnostics platform. This capital infusion is expected to accelerate the company's mission to enhance global healthcare standards by expanding the reach of its advanced diagnostic tools, particularly in POC testing segments. The company's focus on co-development with partners suggests a strategy geared towards market penetration and the widespread adoption of its transformative technologies in disease detection and management.
See full Surfix company page
